FibroBiologics Receives European Patent Titled Methods Of Enhancing Fibroblast Therapeutic Activity

FibroBiologics, Inc. (Nasdaq: FBLG) has been granted European Patent No. 3568465 by the European Patent Office, which focuses on methods to enhance the therapeutic activity of fibroblasts. This patent includes techniques for improving fibroblast efficacy in cell and tissue regeneration by using platelet-rich plasma and specific cytokines, such as FGF-alpha and FGF-beta. The patent also addresses claims related to angiogenesis and spinal disc regeneration.